A clinical-stage biotech with irregular income and equity-funded development
Across the multi-year record, collaboration-related income has been small and uneven relative to recurring operating and research costs. Equipment spending is minimal, but ongoing losses mean development relies on available cash and equity financing; one-off transactions and associate results can also make net income fluctuate.